The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M05 | Drugs for treatment of bone diseases | |
3
|
M05B | Drugs affecting bone structure and mineralization | |
4
|
M05BX | Other drugs affecting bone structure and mineralization | |
5
|
M05BX05 |
| Active Ingredient |
|---|
|
Burosumab is a recombinant human monoclonal antibody (IgG1) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23). By inhibiting FGF23, burosumab increases tubular reabsorption of phosphate from the kidney and increases serum concentration of 1,25 dihydroxy-Vitamin D. |
| Document | Type | Information Source | |
|---|---|---|---|
| CRYSVITA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| CRYSVITA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.